Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Terra Innovatum Enhances Leadership for Commercial Scale-Up with Appointment of Former AREVA CEO and CFO Kathy Williams
-
Standard Lithium Reports Fourth Quarter and Full Year 2025 Results
-
DJI Avata 360, First 8K 360-Degree FPV Drone Announced, More Info at B&H Photo Video
-
VisionWave Provides Corporate Update on Planned Expansion of Multi-Domain Intelligence Platform Across Defense, Energy, and Autonomous Systems
-
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
-
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
-
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
-
Stop & Shop Celebrates Spring with Seasonal Savings & A Free In-Store Offer
-
FDH Electronics Launches New eCommerce Website
-
Chiesi Global Rare Diseases Receives Positive CHMP Opinion for LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)
-
Arax Investment Partners Adds Omni Financial Advisory Group
-
Willis launches new facility to address limited umbrella capacity in U.S. casualty market
-
Westwood Real Estate Income Fund Celebrates 25-Year Anniversary
-
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
-
JazzCash Onboards Its 1 Millionth Merchant on Pakistan’s National Digital Payments Platform, Advancing the Country’s Cashless Economy
-
ASML reports transactions under its current share buyback program
-
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
-
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
-
Nasdaq Concludes Public Consultation on Nasdaq-100 Index® Methodology
-
Director/PDMR Shareholding
-
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
-
Novo Nordisk A/S - share repurchase programme
-
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
-
Virtuix Signs Cooperative Research and Development Agreement with U.S. Navy
-
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
-
Fancamp Acquires Iron Ore Royalty and Provides Corporate Update
-
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
-
WISeKey’s WISeSat.Space Subsidiary Successfully Launches Its 21st Satellite to Low Earth Orbit with SpaceX
-
Elevar Therapeutics Announces FDA Acceptance for Review of New Drug Application for Lirafugratinib as Second-line Cholangiocarcinoma Treatment
-
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
-
SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026
-
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
-
Drilling intersects 92.6 metres (m) of 0.95 g/t gold
-
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
-
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
-
Bitfarms to Participate in Jefferies Fireside Chat
-
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
-
Bombardier Announces Extension of Consent Solicitation with Respect to its 7.35% Debentures due 2026
-
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
-
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
-
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
-
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
Anavex Life Sciences Provides Comprehensive Regulatory Update
-
Capitalzodiac Unveils "Geo-Matrix" – A Revolutionary Analytical Framework for the Global Strategic Minerals Sector
-
Capitalzodiac Unveils "Geo-Matrix" – A Revolutionary Analytical Framework for the Global Strategic Minerals Sector
-
NEURONES: Declaration of transactions on treasury shares (March 23 to 27, 2026)
-
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
-
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
-
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
-
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
